Literature DB >> 9485248

LVAD power delivery: a percutaneous approach to avoid infection.

R Jarvik1, S Westaby, T Katsumata, D Pigott, R D Evans.   

Abstract

BACKGROUND: Driveline infection limits the event-free survival of patients with a left ventricular assist device. With the evolving prospect of improved left ventricular assist devices in the bridge-to-transplantation or recovery setting, we sought to reduce the risk of driveline complications.
METHODS: As part of the Oxford Jarvik 2000 research program, we developed a carbon and then titanium pedestal to transmit the electric wires through the skin. In a sheep model, the pedestal was brought out through the skin of the shoulder (n = 10) or the scalp (n = 9) with underlying fixation to the skull. Exit wounds were carefully inspected for healing and infection. Power cable durability tests were performed in 6 additional animals without an implanted pump.
RESULTS: The cumulative observation period was 1,491 days (mean time, 78 days; range, 14 days to 198 days). There was no difference in observation period between the two groups. Infection (n = 2) and impaired healing (n = 5) occurred in the mobile tissues at the shoulder. Skull-mounted pedestals were free from infection or healing problems. The electric cables were not interrupted by repeated neck flexion (cumulative observation period, 588 days). The carbon pedestal was replaced by a titanium pedestal when the head butting of the sheep fractured the carbon.
CONCLUSIONS: The combination of rigid fixation and highly vascular scalp skin reduces the risk of percutaneous driveline infection and may solve an important outstanding problem in use of left ventricular assist devices.

Entities:  

Mesh:

Year:  1998        PMID: 9485248     DOI: 10.1016/s0003-4975(97)01343-x

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  8 in total

Review 1.  Non-transplant surgery for heart failure.

Authors:  S Westaby
Journal:  Heart       Date:  2000-05       Impact factor: 5.994

2.  Heart failure: Continuous-flow LVADs improve clinical outcomes.

Authors:  Yukihiko Nosé
Journal:  Nat Rev Cardiol       Date:  2010-04       Impact factor: 32.419

Review 3.  Total artificial hearts: past, present, and future.

Authors:  William E Cohn; Daniel L Timms; O H Frazier
Journal:  Nat Rev Cardiol       Date:  2015-06-02       Impact factor: 32.419

4.  Left ventricle assist devices and driveline's infection incidence: a single-centre experience.

Authors:  Jonida Bejko; Francesca Toto; Dario Gregori; Gino Gerosa; Tomaso Bottio
Journal:  J Artif Organs       Date:  2017-10-07       Impact factor: 1.731

5.  Jarvik 2000 with postauricular cable as destination therapy: first clinical case in Japan.

Authors:  Keitaro Domae; Koichi Toda; Ryohei Matsuura; Shigeru Miyagawa; Yasushi Yoshikawa; Hiroki Hata; Shunsuke Saito; Daisuke Yoshioka; Fusako Sera; Kei Nakamoto; Satoru Oshino; Haruhiko Kishima; Yasushi Sakata; Yoshiki Sawa
Journal:  J Artif Organs       Date:  2019-09-13       Impact factor: 1.731

6.  A simple device to secure ventricular assist device driveline and prevent exit-site infection.

Authors:  Andrea Baronetto; Paolo Centofanti; Matteo Attisani; Davide Ricci; Baudolino Mussa; Roger Devotini; Erika Simonato; Mauro Rinaldi
Journal:  Interact Cardiovasc Thorac Surg       Date:  2014-01-14

7.  A novel approach to reduce catheter-related infection using sustained-release basic fibroblast growth factor for tissue regeneration in mice.

Authors:  Keiichi Hirose; Akira Marui; Yoshio Arai; Takamasa Nomura; Kozo Kaneda; Yu Kimura; Tadashi Ikeda; Masatoshi Fujita; Masao Mitsuyama; Yasuhiko Tabata; Masashi Komeda
Journal:  Heart Vessels       Date:  2007-07-20       Impact factor: 2.037

Review 8.  Systems of conductive skin for power transfer in clinical applications.

Authors:  Andreas P Kourouklis; Julius Kaemmel; Xi Wu; Evgenij Potapov; Nikola Cesarovic; Aldo Ferrari; Christoph Starck; Volkmar Falk; Edoardo Mazza
Journal:  Eur Biophys J       Date:  2021-09-03       Impact factor: 1.733

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.